Please login to the form below
Piqray
This page shows the latest Piqray news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients
Novartis has announced that Piqray (alpelisib) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in combination with Faslodex (fulvestrant) for the treatment of advanced ... The recommendation follows the
Latest news
-
Cosentyx, Entresto drive topline growth for Novartis in Q4
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
-
Novartis raises 2019 guidance as new products gather speed
and Piqray (alpelisib) for breast cancer – that both have blockbuster sales potential.
-
FDA clears Novartis’ new breast cancer drug Piqray
Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... The approval is for Piqray (alpelisib formerly BYL719)
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
